NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: RPGLIFE · data 2026-10-30
RPG Life Sciences Limited
In plain words
Price: 17.7% below its 52-week high of ₹3,127.8.
Delivery: 35.8% of traded shares were kept for delivery over the last 10 sessions, against 44.9% over the last 60.
Latest results: a net profit of ₹30 cr for the quarter ended Mar 2026 (-74.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹734 cr |
| Net profit (last 12 months) | ₹120 cr |
| Sales growth, 3 years (yearly) | 11.3% |
| Profit growth, 3 years (yearly) | 19.4% |
Latest results in brief (Q3 FY26)
RPGLIFE Q3 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹180.03 crore.
Net profit was ₹22.13 crore.
Operating margin was 22.1%.
EPS was ₹13.38.
RPGLIFE के Q3 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹180.03 करोड़।
शुद्ध मुनाफ़ा: ₹22.13 करोड़।
ऑपरेटिंग मार्जिन: 22.1%।
EPS: ₹13.38।
RPGLIFEના Q3 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹180.03 કરોડ.
ચોખ્ખો નફો: ₹22.13 કરોડ.
ઓપરેટિંગ માર્જિન: 22.1%.
EPS: ₹13.38.
Written from the filed numbers. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 36.3% over the last 20 sessions vs 43.3% in the 40 before (0.84x); shares delivered per day 0.96x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Dividend ● Results
- 1 Oct 26Insider SAST disclosure: Clarus Capital I, Clarus Capital I… acquired 37,463 shares -4.6% next session
- 9 Jul 26Dividend Dividend ₹24 (ex-date) +16.5% next session
- 27 Jan 26Results Q3 FY26 results: net profit ₹22.1 cr -8.1% next session
- 27 Jun 25Dividend Dividend ₹20 (ex-date) +2.2% next session
- 7 Mar 25Results Q3 FY25 results: net profit ₹34.9 cr -4.5% next session
- 7 Nov 24Results Q2 FY25 results: net profit ₹4.2 cr -7.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Mar 2026 | ₹177 cr | ₹30 cr | -74.5% | 18.6% | 18.08 |
| Sept 2025 | ₹182 cr | ₹37 cr | — | 21.5% | 22.28 |
| Mar 2025 | ₹143 cr | ₹117 cr | — | 17.8% | 70.96 |
Shareholding trend
| Holder | Jun 2026 | Dec 2025 |
|---|---|---|
| Promoters | 72.95% | 72.95% |
| Foreign institutions (FII) | 0.95% | 1.00% |
| Domestic institutions (DII) | 8.67% | 7.04% |
| Mutual funds | 0.04% | 0.04% |
| Retail investors | 13.68% | 14.97% |
| Number of shareholders | 23,886 | 25,905 |
Common questions
What was RPG Life Sciences Limited's latest quarterly profit?
RPG Life Sciences Limited reported a net profit of ₹30 cr for the quarter ended Mar 2026 (-74.5% on the same quarter a year earlier), on revenue of ₹177 cr.
How much do promoters hold in RPG Life Sciences Limited?
Promoters held 72.95% of RPG Life Sciences Limited at the end of Jun 2026, with 0.00% of promoter shares pledged.
Is RPG Life Sciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.03, which is very low.
What is RPG Life Sciences Limited's P/E ratio?
About 35.6, based on the last 12 months' earnings and a price of ₹2,575.7 (data 2026-10-30).
What is the 52-week high and low of RPG Life Sciences Limited?
The 52-week high is ₹3,127.8 and the 52-week low is ₹1,733.
Similar companies
Senores Pharmaceuticals Ltd. (SENORES) · Orchid Pharma Limited (ORCHPHARMA) · Gujarat Themis Biosyn Ltd (GUJTHEM) · SMS Pharmaceuticals Limited (SMSPHARMA) · Evonile Pharma Limited (NOVARTIND)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open RPGLIFE in NSE Scanner →